Navigation Links
PreMD Inc. Signs Agreement with Cosmetics Conglomerate
Date:3/6/2008

TORONTO, March 6 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; Amex: PME) today announced that it has entered into a collaboration with one of the world's largest beauty companies. The agreement is for skincare devices using PreMD's innovative skin testing technologies, to enhance the capabilities of cosmetic compounds. Financial details and the name of the organization are not being disclosed at this time.

"This is a very positive development for PreMD," said Brent Norton, president and CEO of PreMD. "To engage in research and testing with one of the world's leading cosmetics companies is a significant development which validates our expertise in skin testing, exposes our product capabilities to new markets, and opens the door to further commercial partnerships. We are excited by the prospect of developing new technologies in the cosmetics field and we are looking forward to capitalizing on these and other opportunities in the near future."

Dr. Norton continued, "Not only does this agreement validate our international intellectual property portfolio, it also expands our capabilities in the marketplace as we hope to complete additional agreements with the inclusion of commercial terms."

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include a line of non-invasive skin cholesterol tests. PreMD's other skin cholesterol products include PREVU(x) LT, a skin cholesterol test designed for use in the life insurance industry. The Company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit htt
'/>"/>

SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. PreMD Inc. Announces Debenture Financing
2. PreMD Initiates FDA Review Process and Provides Corporate Update
3. PreMD Announces FDA Decision on POC Skin Cholesterol Test
4. PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product
5. PreMD Inc. Provides Corporate Update
6. PreMD Provides Update on 510(k) Application for PREVU(x) POC
7. Osteotech Signs Agreement To Distribute Harvest Technologies BMAC(TM) System
8. Whitemark Homes Signs Letter of Intent to Acquire Metiscan Holdings, Inc.
9. International Soccer Superstar Ronaldinho Signs With Nutrilite(TM)
10. Siemens Signs New Revenue Cycle Management Customers
11. Alimera Sciences Signs Second Agreement With Emory University for Potential Treatments Using New Class of Antioxidants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...effective against Lennox-Gastaut syndrome , ...ug called Banzel (rufinamide) has been approved as...ilepsy called Lennox-Gastaut syndrome, the U.S. Fo...The approval was based on results of a four-month .... Compared to patients who took a placebo, those w...
(Date:11/21/2008)...PRNewswire-USNewswire/ -- New research at West Vi...s, spitless tobacco product aimed at young adults ...t RJ Reynolds, Camel Snus - touted as a socially a...risingly high levels of nicotine. , , "Came...f products," said Bruce Adkins of the state Divisi...
(Date:11/21/2008)...ewswire-USNewswire/ -- U.S. News & World Repor... (NCQA) ranked BlueChoice(R) HealthPlan of South C...Plans(TM), published in U.S. News & World Repo...ual ranking ranks the nation,s best health plans b...NCQA accreditation scores. NCQA and U.S. News &...
(Date:11/21/2008)...ewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (...s overwhelmingly approved the proposals submitted ...a Pharmaceuticals Industries Ltd. (Nasdaq: TEVA ...whelming support of the transaction by the Barr sh... and CEO. "We are pleased with the progress that w...
Breaking Medicine News(10 mins):Health News:FDA Approves New Drug for Severe Epilepsy 2Health News:Experts Say New Tobacco Product Targets Young Adults 2Health News:Experts Say New Tobacco Product Targets Young Adults 3Health News:BlueChoice HealthPlan Ranks in Top Third of America's Best Health Plans 2Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
...rganization (NACO) of India plans to promote the d...attle against HIV/AIDS//. The third phase of the N...y to be launched in April. Statistics show that ...the private sector for outpatient care and over 50...
...fusal of surgery to known smokers is all set to be...ating the issue in this week’s BMJ//. The issue wa...t last year to remove smokers from the waiting lis...Peters who is from Concord Repatriation General Ho...
...on therapy on the exterior along with radiation se...highly effective// for treatment of prostate cance...of Radiation Oncology Biology Physics has revealed...undergone such a combination therapy have been com...
...or Disease Control and Prevention (CDC) Atlanta's ...is time the US changed its guidelines// and made T...irrespective of how long they have been residing t...ated if all foreign-born residents from high-risk ...
Other Medicine News:Health News:Refusal of Surgery for Smokers – To Be or Not to Be 2Health News:All Foreign-born Nationals In US To Be Tested For TB 2
(Date:11/21/2008)...England, November 21 , ...an Committee for Medicinal Products for Human Use ...n for the approval of Enbrel(R),(etanercept) as a...,adolescents with severe plaque psoriasis. If appr...mmittee,s recommendation, Enbrel will become the,...
(Date:11/20/2008)... , , PHILADELPHIA, Nov. 20 /PRNewswire-Firs...unced that the United States Food and Drug Adminis...MACTA(R) (eltrombopag) for the treatment of thromb...thic) thrombocytopenic purpura (ITP) who have had ...oglobulins or splenectomy. The approval is a signi...
(Date:11/20/2008)...lif., Nov. 20 Duska Ther...nced today that it has submitted its,pivotal Phas...r a Special,Protocol Assessment (SPA) procedure w..., Subject to securing an agreement with the...tive, double-blind, placebo-controlled and randomi...
(Date:11/19/2008)...O, Nov. 19 Posit Science Corporati...the Society for Neuroscience,Annual Conference in...e,training may benefit Baby Boomers. The compute...m (TM) uses adaptive exercises that target auditor...ed to drive generalized,improvements in cognition...
Breaking Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4New Evidence That Brain-Plasticity Based Training has Broad Impact: Improved Cognition in Boomers, Improved Motor Control in Older Adults 2Pregnant mice block out unwelcome admirers to protect their pups 4122 1Pregnant mice block out unwelcome admirers to protect their pups 4122 2Capella University Launches Online PhD Specialization in Nursing Education 24214 1Capella University Launches Online PhD Specialization in Nursing Education 24214 2Capella University Launches Online PhD Specialization in Nursing Education 24214 3Incidence of Mantle Cell Lymphoma on Rise 24211 1Incidence of Mantle Cell Lymphoma on Rise 24211 2Breast Fed Babies Have Fewer GI Infections 24208 1Breast Fed Babies Have Fewer GI Infections 24208 2
...roach to Address Growing Problem of Antibiotic Res...ER, British Columbia, March 26, 2007 /PRNewswire/ ... IDR-1 is the first,immune system trigger to cure ...ccording to a paper published in the April 2007,is...ghlights the work of Inimex and its,co-founders Dr...
...rial Shows CRESTOR Slowed Progression Of Atheroscl...sease , LONDON, March 26, 2006-AstraZeneca today a... is the first study to show a,positive effect on a...id artery disease and at low risk of coronary hear...uvastatin) 40mg and presented at,56th Scientific S...
Other Medicine Technology:Inimex Product Candidate is First Immune Defense Regulator to Cure,Infections Without Causing Harmful Inflammation 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 2First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 3First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 4First Study To Show Positive Benefit On Atherosclerosis For People,With Early Signs Of Diseased Arteries 5
Grafton DBM Matrix PLF is the first bone graft material designed specifically for posterolateral fusion procedures. Unique trough-like design allows for easy use with allograft/autograft bone. Demine
Demineralized bone matrix dispensed in a jar. Fibers will be free of foreign matter. Glycerol 70-88% by weight. Calcium content less than 8%.
Demineralized bone matrix dispensed in a syringe. DBM will be free of foreign matter. Demineralized bone matrix particle size 125 to 850 . Glycerol 70-88% by weight. Calcium content less than 8%.
Inductive demineralized bone matrix and conductive cancellous chips. DBM and cancellous chips will be free of foreign matter. Demineralized bone matrix particle size is 125 to 1000 . Cancellous chip
Medicine Products: